The Effect of Addition of Metformin to SGLT2 In Diabetic Patients With Heart Failure With Preserved Ejection Fraction

PHASE2/PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

November 1, 2023

Primary Completion Date

November 1, 2024

Study Completion Date

December 1, 2024

Conditions
Heart Failure With Preserved Ejection FractionDiabete Type 2
Interventions
DRUG

Metformin

The intervention will consist in giving metformin starting with 500 mg once daily 1 gm daily (at breakfast) during the first week; if well tolerated, the dose was progressively increased to 500 mg twice daily (at breakfast and dinner) during week 2, to 1000 mg at breakfast and 500 mg at dinner during week 3, in order to reach the target dose of 1000 mg twice daily (at breakfast and dinner) during the rest of the follow-up. Patients will be followed up by telephone call 2 weeks intervals during the study period 5 SGL-2 will be prescribed to group 1 after diagnosis with HFpEF while group 2 will have SGL-2 and Metformin

Trial Locations (1)

Unknown

clinical research uint- El-sheikh zayed specialized hospital SMC- Egyptian Ministry of health, Cairo

All Listed Sponsors
collaborator

clinical research unit, El-sheikh zayed specialized hospital - Egyptian Ministry of health

UNKNOWN

lead

October University for Modern Sciences and Arts

OTHER

NCT06080802 - The Effect of Addition of Metformin to SGLT2 In Diabetic Patients With Heart Failure With Preserved Ejection Fraction | Biotech Hunter | Biotech Hunter